Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23428554 | 0.94 | SCN8A (0.44) | CHRM2HRH4HRH3SCN8ASMN1; SMN2 | |
| SCHEMBL19865635 | 0.83 | SMN1; SMN2 (0.54) | CHRM2HRH4HRH3LMNACYP1A2 | |
| SCHEMBL4620705 | 0.82 | SCN8A (0.42) | CHRM2SCN8ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2082460 | 0.81 | NOS3 (0.45) | SCN8A | |
| SCHEMBL20482639 | 0.81 | ADORA2A (0.45) | CHRM2SCN8ASMN1; SMN2 | |
| SCHEMBL2261106 | 0.80 | NOS3 (0.41) | — | |
| SCHEMBL6839265 | 0.78 | TDP1 (0.49) | LMNASMN1; SMN2MEN1KMT2AALOX12 | |
| SCHEMBL29148471 | 0.78 | TDP1 (0.49) | LMNASMN1; SMN2MEN1KMT2AALOX12 | |
| SCHEMBL26464914 | 0.78 | TDP1 (0.49) | LMNASMN1; SMN2MEN1KMT2AALOX12 | |
| SCHEMBL27876571 | 0.78 | TDP1 (0.49) | LMNASMN1; SMN2MEN1KMT2AALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | CHRM2 1925/4885HRH4 4072/4885HRH3 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.